文献速递系统性红斑狼疮

狼疮肾脏活动指数在成人SLE与狼疮肾炎中识别活动性肾病及治疗反应

The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-02-23

在TULIP-LN与TULIP-1研究中,基线时活动性LN组(n=128)RAIL评分中位数5.59高于活动性非肾性SLE对照组(n=48)的3.57(P<0.001)。第12和24周,应答者RAIL评分较基线的下降幅度均显著大于无应答者(PRR、CRR、UPCR50:所有P<0.0006)。

要点

  • 基线RAIL评分活动性LN组5.59高于非肾性SLE组3.57(P<0.001)。
  • 第12和24周,应答者RAIL评分较基线的下降幅度显著大于无应答者(P<0.0006)。
  • CRR者第12周RAIL评分中位下降-1.3,无应答者下降-0.39。

核心结论

  • RAIL可识别成人活动性狼疮肾炎,并纵向区分治疗应答。

研究设计与样本

  • 使用TULIP-LN(NCT02547922)活检证实的活动性III/IV型LN成人尿液样本(活动LN组)和TULIP-1(NCT02446912)活动性非肾性SLE成人尿液样本(活动SLE组)。
  • 测量尿RAIL生物标志物:中性粒细胞明胶酶相关脂质运载蛋白、肾损伤分子1、单核细胞趋化蛋白1、脂联素、血红素结合蛋白和铜蓝蛋白。
  • 两项研究均测基线,仅TULIP-LN测第12和24周。
  • 基线时比较两组,并比较活动LN组内无应答者与应答者(CRR、PRR、UPCR50)RAIL评分较基线的变化。

主要发现

  • 基线时活动LN组(n=128)RAIL生物标志物中位浓度显著高于SLE对照组(n=48)(P≤0.02)。
  • 基线RAIL评分活动LN组5.59(IQR 4.31-6.47)高于SLE对照组3.57(IQR 2.78-4.47)(P<0.001)。
  • 第12和24周分别有25和31例CRR、39和54例PRR、41和63例UPCR50。
  • 第12和24周RAIL评分较基线变化在无应答者与应答者间显著不同(PRR、CRR、UPCR50:所有P<0.0006),应答者评分更低。
  • CRR者第12周RAIL评分中位变化-1.3(IQR -3.64至-0.21),无应答者-0.39;第24周分别为-2.30(IQR -3.63至-1.03)和-0.88(IQR -2.20至0.33)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the ability of the Renal Activity Index for Lupus (RAIL) to discriminate active lupus nephritis (LN) in adult patients with active systemic lupus erythematosus (SLE) and differentiate LN treatment response. METHODS: Urine samples from adults with biopsy-proven active class III and IV LN from TULIP-LN (active LN group; ClinicalTrials.gov identifier: NCT02547922) and adults with active, nonrenal SLE from TULIP-1 (active SLE group; ClinicalTrials.gov identifier: NCT02446912) were used, and RAIL biomarkers (neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, monocyte chemotactic protein 1, adiponectin, hemopexin, and ceruloplasmin) were measured in the urine at baseline for both studies and at weeks 12 and 24 for TULIP-LN only. The groups were compared at baseline, and changes in RAIL scores from baseline in the active LN group were compared between nonresponders and responders over time, ie, those with complete renal response (CRR), partial renal response (PRR), and urine protein-creatine ratio decrease ≥50% (UPCR50). RESULTS: At baseline, median (interquartile range [IQR]) concentrations of RAIL biomarkers were significantly higher (P ≤ 0.02) in the active LN group (n = 128) versus the SLE control group (n = 48), as were RAIL scores (5.59 [IQR 4.31-6.47] vs 3.57 [IQR 2.78-4.47]; P < 0.001). At weeks 12 and 24, there were 25 and 31 patients with CRR, 39 and 54 patients with PRR, and 41 and 63 patients with UPCR50, respectively. Changes in RAIL scores from baseline to weeks 12 and 24 significantly differed between nonresponders and responders (PRR, CRR, UPCR50: all P < 0.0006), with lower scores in responders. For CRR versus non-response, median [IQR] RAIL scores decreased by -1.3 (-3.64 to -0.21) versus -0.39 at week 12, and -2.30 (-3.63 to -1.03) versus -0.88 (-2.20 to 0.33) at week 24, respectively. CONCLUSIONS: The RAIL identifies active LN and longitudinally differentiates treatment response in adults with LN.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Brunner HI, Cody EM, Devarajan P, et al. The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Care Res (Hoboken). 2026. PMID: 41144892. doi:10.1002/acr.25684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。